Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Nivolumab and CAPOX in Patients With FGFR2/PD-L1-positive Metastatic Gastric Adenocarcinoma: a Single-arm, Phase 2 Study

NCT05859477 is registered in ClinicalTrials.gov with Kidney Cancer Research Bureau as lead sponsor.

NCT NCT05859477
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05859477 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Nivolumab and CAPOX in Patients With FGFR2/PD-L1-positive Metastatic Gastric Adenocarcinoma: a Single-arm, Phase 2 Study
Lead sponsor
Kidney Cancer Research Bureau
Phase
Phase 2
Overall status
Unknown status
Start date
June 5, 2022
Completion date
December 1, 2024
Enrollment
23 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

fgfr2 amplification, metastatic gastric cancer, pd-l1 gene amplification